Experience With the Priority Review Voucher Program for Drug Development

JAMA. 2015 Oct 27;314(16):1687-8. doi: 10.1001/jama.2015.11845.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antimalarials / economics
  • Antineoplastic Agents / economics
  • Antiprotozoal Agents / economics
  • Antitubercular Agents / economics
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins / economics
  • Cholic Acid / economics
  • Chondroitinsulfatases / economics
  • Diarylquinolines / economics
  • Drug Approval / economics*
  • Drug Approval / legislation & jurisprudence
  • Drug Approval / methods
  • Drug Combinations
  • Drug Industry / economics*
  • Drug Industry / legislation & jurisprudence
  • Ethanolamines / economics
  • Fluorenes / economics
  • Humans
  • Neglected Diseases / drug therapy*
  • Phosphorylcholine / analogs & derivatives
  • Phosphorylcholine / economics
  • Program Development / economics*
  • Rare Diseases / drug therapy*
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antimalarials
  • Antineoplastic Agents
  • Antiprotozoal Agents
  • Antitubercular Agents
  • Artemether, Lumefantrine Drug Combination
  • Artemisinins
  • Diarylquinolines
  • Drug Combinations
  • Ethanolamines
  • Fluorenes
  • Phosphorylcholine
  • miltefosine
  • bedaquiline
  • dinutuximab
  • Chondroitinsulfatases
  • GALNS protein, human
  • Cholic Acid